imipramine has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 2 studies
Imipramine: The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.
imipramine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Here, we demonstrate that the anti-depressant imipramine blocks growth of triple-negative (TNBC) and estrogen receptor-positive (ER+) breast cancers by inducing cell cycle arrest and by blocking heightened homologous recombination (HR) and non-homologous end joining-mediated (NHEJ) DNA repair activities." | 8.12 | The antidepressant imipramine inhibits breast cancer growth by targeting estrogen receptor signaling and DNA repair events. ( Abdelfattah, N; Brenner, A; Chen, Y; Jatoi, I; Kaklamani, V; Nirzhor, S; Rajamanickam, S; Rao, A; Rao, MK; Subbarayalu, P; Timilsina, S; Vadlamudi, R; Viswanadhapalli, S, 2022) |
| " Here, we demonstrate that the anti-depressant imipramine blocks growth of triple-negative (TNBC) and estrogen receptor-positive (ER+) breast cancers by inducing cell cycle arrest and by blocking heightened homologous recombination (HR) and non-homologous end joining-mediated (NHEJ) DNA repair activities." | 4.12 | The antidepressant imipramine inhibits breast cancer growth by targeting estrogen receptor signaling and DNA repair events. ( Abdelfattah, N; Brenner, A; Chen, Y; Jatoi, I; Kaklamani, V; Nirzhor, S; Rajamanickam, S; Rao, A; Rao, MK; Subbarayalu, P; Timilsina, S; Vadlamudi, R; Viswanadhapalli, S, 2022) |
| "Imipramine is a tricyclic antidepressant that possesses anti-inflammatory activity and has been reported to inhibit the progression of highly metastatic non-small cell lung cancer." | 1.91 | Imipramine Induces Apoptosis and Inhibits the Metastatic Potential of Triple-negative Breast Cancer Cells. ( Chen, SK; Chen, WT; Hsu, FT; Lee, W; Li, YC, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Timilsina, S | 1 |
| Rajamanickam, S | 1 |
| Rao, A | 1 |
| Subbarayalu, P | 1 |
| Nirzhor, S | 1 |
| Abdelfattah, N | 1 |
| Viswanadhapalli, S | 1 |
| Chen, Y | 1 |
| Jatoi, I | 1 |
| Brenner, A | 1 |
| Rao, MK | 1 |
| Vadlamudi, R | 1 |
| Kaklamani, V | 1 |
| Chen, SK | 1 |
| Lee, W | 1 |
| Li, YC | 1 |
| Hsu, FT | 1 |
| Chen, WT | 1 |
2 other studies available for imipramine and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
The antidepressant imipramine inhibits breast cancer growth by targeting estrogen receptor signaling and DNA repair events.
Topics: Animals; Antidepressive Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA Repair; | 2022 |
Imipramine Induces Apoptosis and Inhibits the Metastatic Potential of Triple-negative Breast Cancer Cells.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Huma | 2023 |